
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$620.05
+US$8.00 · +1.31%
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
前收盘价
US$620.05
+US$8.00 · +1.31%
盘前
US$620.05
US$0.00 · 0.00%
10月13日 4:11 ET
盘中时间采用ET。市场数据可能有所延迟。
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
日内区间
当前US$620.05
52周区间
当前US$620.05
盘中时间采用ET。市场数据可能有所延迟。
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
日内区间
当前US$620.05
52周区间
当前US$620.05
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 25.3亿 USD | 21.09亿 USD | 18.86亿 USD | 14.6亿 USD | 11.42亿 USD |
| 销货成本 | 17.7亿 USD | 14.53亿 USD | 13.61亿 USD | 10.28亿 USD | 8.14亿 USD |
| 毛利 | 7.61亿 USD | 6.56亿 USD | 5.25亿 USD | 4.32亿 USD | 3.28亿 USD |
| 销售、一般及管理费用 | 1.98亿 USD | 1.8亿 USD | 1.61亿 USD | 1.31亿 USD | 1.08亿 USD |
| 营业费用 | 2.26亿 USD | 2.09亿 USD | 1.88亿 USD | 1.54亿 USD | 1.3亿 USD |
| 利息收入 | — | 2499.6万 USD | — | — | — |
| 利息支出 | — | — | 48.8万 USD | 290.5万 USD | 10.5万 USD |
| 折旧和摊销 | 2812.4万 USD | 2925.1万 USD | 2632.8万 USD | 2234.1万 USD | 2111.9万 USD |
| 营业利润 | 5.35亿 USD | 4.47亿 USD | 3.37亿 USD | 2.79亿 USD | 1.99亿 USD |
| 净利润 | 4.51亿 USD | 4.04亿 USD | 2.83亿 USD | 2.45亿 USD | 1.82亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$620.44
上涨空间 0.06%AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。